OV’s clinical data on PARP inhibitor 2X-121 and response prediction validation to be presented on the world’s largest cancer congress ASCO 2018
Hoersholm, Denmark, June 1, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”) today announced that clinical data on PARP inhibitor 2X-121 and response prediction validation is to be presented on the world’s largest cancer congress ASCO 2018 on June 1st 2018. Oncology Venture in-licensed the active PARP inhibitor E7449 now called 2X-121 from Eisai in Q2 2017 and present clinical data as well as data demonstrating validation of Oncology Ventures novel DRP®s ability to identify the patients who will benefit from 2X-121 therapy. “We are very proud that we can already now present